Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates

British Journal of Pharmacology

Volumn 127, Issue 5, 1999, Pages 1129-1134

  Matsuno, Hiroyuki ^a   Kozawa, Osamu ^a   Nagashima, Satoru ^b   Kanamaru, Mitutaka ^b   Uematsu, Toshihiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sitro Hospital   (Japan)

Author keywords

GPIIb IIIa antagonist; Microaggregation; Platelets

Indexed keywords

4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; ACETYLSALICYLIC ACID; VAPIPROST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTERY OCCLUSION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; FEMORAL ARTERY; HAMSTER; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANIMALS; ASPIRIN; BIPHENYL COMPOUNDS; CRICETINAE; FIBRINOLYTIC AGENTS; HEPTANOIC ACIDS; MALE; PIPERAZINES; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 0032792961     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702651     Document Type: Article

References (22)

1. ADRIE, C., BLOCH, K.D., MORENO, P.R., HURFORD, W.E., GUERRERO, J.L., HOLT, R., ZAPOL, W.M., GOLD, H.K. & SEMIGRAN, M.J. (1996). Inhaled nitric oxide increases coronary artery patency after thrombolysis. Circulation, 94, 1919-1926.
2. ARMSTRONG, R.A., HUMPHREY, P.P. & LUMLEY, P. (1993). Characteristics of the binding of [3H]-GR32191 to the thromboxane(TP-) receptor of human platelets. Br. J. Pharmacol., 110, 539-547.
3. BORN, G.V. & HUME, M. (1967). Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature, 215, 1027-1029.
4. CARDINAL, D.C. & FLOWER, R.J. (1979). The study of platelet aggregation in whole blood. Br. J. Pharmacol., 66, 94P-95P.
5. FRESSINAUD, E. & MEYER, D. (1991). von Willebrand factor and platelet interactions with the vessel wall. Blood Coagulation & Fibrinolysis, 2, 333-340.
6. KAWASAKI, T., SAKAI, Y., TANIUCHI, Y., SATO, K., MARUYAMA, K., SHIMIZU, M., KAKU, S., YANO, S., INAGAKI, O., TOMIOKA, K., YANAGISAWA, I. & TAKENAKA, T. (1996). Biochemical characterization of a new disintegrin, flavostatin, isolated from Trimeresurus flavoviridis venom. Biochimie, 78, 245-252.
7. LATIMER, P. (1979). Light scattering vs. microscopy for measuring average cell size and shape. Biophys. J., 27, 117-126.
8. LATIMER, P., BORN, G.V. & MICHAL, P. (1977). Application of light-scattering theory to the optical effects associated with the morphology of blood platelets. Arch. Biochem. Biophys., 180, 151-159.
9. LETHAGEN, S. & KLING, S. (1993). New bleeding time devices with retractable blades evaluated in children, healthy volunteers and patients with prolonged bleeding time. Thromb. Haemost., 70, 595-597.
10. MATSUNO, H., KOZAWA, O., NIWA, M., ITO, T., TANABE, K., NISHIDA, M., HAYASHI, H. & UEMATSU, T. (1998). Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster. J. Cardiovasc. Pharmacol., 32, 191-197.
11. MATSUNO, H., KOZAWA, O., NIWA, M. & UEMATSU, T. (1997). Inhibition of von Willebrand factor binding to platelet GP 1b by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation, 96, 1299-1304.
12. MATSUNO, H., UEMATSU, T. & NAKASHIMA, M. (1993). Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model. Br. J. Pharmacol., 110, 1278-1279.
13. MATSUNO, H., UEMATSU, T., UMEMURA, K., TAKIGUCHI, Y., WADA, K. & NAKASHIMA, M. (1992). Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br. J. Pharmacol., 106, 533-538.
14. MENYS, V.C., BELCHER, P.R., NOBLE, M.I., EVANS, R.D., DROSSOS, G.E., PILLAI, R. & WESTABY, S. (1994). Macroaggregation of platelets in plasma, as distinct from microaggregation in whole blood (and plasma), as determined using optical aggregometry and platelet counting respectively, is specifically impaired following cardiopulmonary bypass in man. Thromb. Haemost., 72, 511-518.
15. NICOLINI, F.A., NICHOLS, W.W., MEHTA, J.L., SALDEEN, T.G., SCHOFIELD, R., ROSS, M., PLAYER, D.W., POHL, G.B. & MATTSSON, C. (1992). Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator. J. Am. Coll. Cardiol., 20, 228-235.
16. OZAKI, Y., SATOH, K., YATOMI, Y., YAMAMOTO, T., SHIRASAWA, Y. & KUME, S. (1994). Detection of platelet aggregates with a particle counting method using light scattering. Anal. Biochem., 218, 284-294.
17. RUGGERI, Z.M. (1997). Mechanisms initiating platelet thrombus formation. Thromb. Haemost., 78, 611-616.
18. SCHAFER, A.I. (1996). Antiplatelet Therapy. Am. J. Medicine., 101, 199-209.
19. SMITH, J.B. & WILLIS, A.L. (1971). Aspirin selectively inhibits prostaglandin production in human platelets. Nature, 231, 235-237.
20. TOHGI, H., TAKAHASHI, H., WATANABE, K., KUKI, H. & SHIRASAWA, Y. (1996). Development of large platelet aggregates from small aggregates as determined by laser-light scattering: effects of aggregant concentration and antiplatelet medication. Thromb. Haemost., 75, 838-843.
21. TOPOL, E.J. (1995). Novel antithrombotic approaches to coronary artery disease. Am. J. Cardiol., 75, 27B-33B.
22. WHITE, B.P., SULLIVAN, A.T. & LUMLEY, P. (1994). Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin. Thromb. Haemost., 71, 366-374.